In 2023, Dr Anna Wilkins and Dr Erik Sahai successfully completed their PCR project. They proved that their technology can identify patterns which mean someone’s cancer may be more likely to return. This marks a huge step forward for more personalised treatment. The researchers will now take their technology forward to make it work even better and test it using tissue from men with advanced disease.
Completed Research Projects
Find out more about some of the research projects we have funded in the past and the progress they have made for people affected by prostate cancer.
AI: Will my cancer return?
Dr Anna Wilkins and Dr Erik Sahai
Dates: June 2021 – January 2023
Location: Francis Crick Institute, London
Amount: £100,000
Sometimes cancer returns following treatment, but doctors cannot predict which will return. If we could predict this, we could make sure that those with a high risk of cancer returning can have their treatment changed to reduce their risk and those with a low risk can avoid overtreatment and associated side effects.
Studies have found patterns in the prostate tissue that can predict whether a cancer is likely to return. Identifying these patterns needs to be done by a highly skilled individual, and it is time consuming and expensive.
Dr Wilkins and Dr Sahai developed computer software to do this automatically and quickly. The researchers used the software to analyse tissue samples collected from patients with prostate cancer during the CHHiP clinical trial. They proved that their software works and can identify patterns associated with prostate cancer returning.
Dr Wilkins and Dr Sahai will now be testing their software further. They will prove that it can analyse a wide range of patient tissue, for example, by testing it using tissue from men who have more advanced prostate cancer. They will also continue to make improvements and make the software work even better.
Immunotherapy for prostate cancer
Dr Christine Galustian
Dates: March 2020 – July 2022
Location: King’s College, London
Amount: £400,000
2022 marked the successful completion of Dr Christine Galustian and Dr Efthymia Papaevangelou’s project. They developed a novel immunotherapy which successfully treated both local tumours and cancer that had spread in mice. As a result of our funding and guidance, this treatment will now be tested in humans in a clinical trial.
Immunotherapy harnesses the body’s own immune system to fight cancer. Unfortunately, the biology of the prostate means that it has ben difficult to get immunotherapy to work in prostate cancer.
Drs Galustian, Papaevangelou, and Esteves experimented with a new form of immunotherapy in which they attached an immunity protein called IL-15 to a chemical “tail” which anchored it to the place where it was injected. They hoped this would make it both safer and more effective than other forms of immunotherapy.
The team discovered that when they combined their tailed IL-15 with another drug that affects the immune system, it increased survival in mice by 90% and proved that tumours which were successfully treated with this combination did not grow back. They also gathered important insights into how this therapy affects the biology of the tumour.
Based on their promising results, Dr Galustian has just received funding to develop a clinical trial, to start establishing is this therapy is as safe and effective in humans as it is in mice.
Prostate Cancer Stem Cells
Dr Aamir Ahmed
Dates: May 2018 – September 2021
Location: King’s College, London
Amount: £660,516
2021 marked the conclusion of Dr Aamir Ahmed’s project. This team’s work added to the evidence that Wnt signalling plays an important role in prostate cancer, and worked on an objective and quantitative method to identify new protein biomarkers to help predict prostate cancer prognosis.
Cancer stem cells produce cancer cells and divide continuously to drive tumour growth. They can also survive treatment and restart tumour growth when treatment has stopped.
Wnt signalling is one way your cells communicate and is important in regulating stem cells.
This team tested drugs used in other illnesses to see if they could stop Wnt signalling in prostate cancer.
In addition to his research work, Dr Ahmed has been a good friend to PCR and its supporters, having hosted many lab tours and met many of our supporters and patients.
Modelling Prostate Cancer
Professor Matthew Smalley and Dr Boris Shorning
Dates: October 2017 – January 2021
Location: Cardiff University
Amount: £335,895
2021 marked the successful conclusion of Professor Matt Smalley and Dr Boris Shorning’s project. We are incredibly proud of what they have achieved, and of how well they collaborated with other PCR researchers. The insights they gained into why cancers spread and the potential for an anti-diabetes drug in prostate cancer give the field a clear direction towards new therapies.
Professor Matt Smalley and Dr Boris Shorning developed innovative, world-first models to test the effectiveness of treatments for metastatic prostate cancer, to see if they are good enough and safe enough to move into humans.
Over the three years of this project, they collaborated extensively with other PCR researchers, and played a crucial role in testing compounds developed by other researchers to see if they prevented prostate cancer growth.
They also provided critical insights into the role of Plexin B1, a molecule which controls how cells respond to their environment. They compared two forms of Plexin B1 (normal and mutated), to see which increases metastasis.
They showed that increased levels of the mutated, but not the normal form, stimulates cancer to advance, and, looking at patient data, they discovered that patients with mutated Plexin B1 have worse outcomes compared to patients without Plexin B1 mutations.